$-0.47
(Market cap
$16 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
9.3
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-5.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0
-
Debt to Equity
--
-
Book Value
$--
-
EPS
$-6.3
-
Face value
--
-
Shares outstanding
2,278,620
10 Years Aggregate
CFO
$-40.48 Mln
EBITDA
$7.02 Mln
Net Profit
$-25.94 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Portage Biotech (PRTG)
| -9.1 | -21.0 | -19.9 | -6.2 | -67.5 | -51.8 | -23.5 |
|
BSE Sensex*
| -10.8 | -0.6 | -1.7 | -8.5 | 6.4 | 7.6 | 11.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Portage Biotech (PRTG)
| -65.6 | -50.7 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Portage Biotech (PRTG)
|
4.7 | 15.5 | 0.0 | -6.8 | -- | -347.1 | -- | 9.3 |
| 11.8 | 1,711.9 | 0.0 | -647.7 | -- | -- | -- | 12.9 |
Shareholding Pattern
View DetailsAbout Portage Biotech (PRTG)
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1... positive tumors; PORT-6, a highly selective A2A receptor antagonist, which is in phase 1a for the treatment of solid tumors; PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials; and PORT-7, a potent and selective antagonist of the adenosine A2B receptor. Portage Biotech Inc. is based in Tortola, British Virgin Islands. Read more
-
CEO & Chairman of Board
Dr. Ian B. Walters M.B.A., M.D.
-
CEO & Chairman of Board
Dr. Ian B. Walters M.B.A., M.D.
-
Headquarters
Tortola
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Portage Biotech (PRTG)
What is the current share price of Portage Biotech Inc (PRTG) Today?
The share price of Portage Biotech Inc (PRTG) is $4.70 (NASDAQ) as of 05-Nov-2025 09:30 EDT. Portage Biotech Inc (PRTG) has given a return of -67.49% in the last 3 years.
What is the current PB & PE ratio of Portage Biotech Inc (PRTG)?
Since, TTM earnings of Portage Biotech Inc (PRTG) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-1.47
|
-80.92
|
|
2024
|
-0.01
|
0.14
|
|
2023
|
-0.52
|
0.72
|
|
2022
|
-5.20
|
0.72
|
|
2021
|
-21.25
|
3.32
|
What is the 52 Week High and Low of Portage Biotech Inc (PRTG)?
The 52-week high and low of Portage Biotech Inc (PRTG) are Rs 15.82 and Rs 2.95 as of 13-Jun-2026.
What is the market cap of Portage Biotech Inc (PRTG)?
Portage Biotech Inc (PRTG) has a market capitalisation of $ 16 Mln as on 05-Nov-2025. As per SEBI classification, it is a Small Cap company.
Should I invest in Portage Biotech Inc (PRTG)?
Before investing in Portage Biotech Inc (PRTG), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.